Using Scans and Tumor Biopsies to Guide Kidney Cancer Treatment Choices
Studies kidney tumor biopsies and MRI scans to guide treatment decisions in renal cell carcinoma.
Plain-language title generated from the registry record
Registry title: Targeted Decision Making In Renal Cell Carcinoma Relying on a Radiogenomics Translational Platform
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- IRCCS Ospedale San RaffaeleMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS San Raffaele
- Trial code
- NCT06868927
- Record updated
- 17 March 2026
- Original description
This project aims to provide an accurate strategy to guide the decision making relying on tumor biopsies using standard histology, immunohistochemistry (IHC), spatial transcriptomics, genomics combined with Magnetic Resonance Imaging (MRI) and radiomics. Moreover, the investigators will explore potential markers indicative of response to systemic agents or ablative therapy.Read full original descriptionShow less
Targeted Decision Making In Renal Cell Carcinoma Relying on a Radiogenomics Translational Platform
This project aims to provide an accurate strategy to guide the decision making relying on tumor biopsies using standard histology, immunohistochemistry (IHC), spatial transcriptomics, genomics combined with Magnetic Resonance Imaging (MRI) and radiomics. Moreover, the investigators will explore potential markers indicative of response to systemic agents or ablative therapy.
Inclusion: Presence of a renal mass up to 4 cm; Adult > 18 years; Candidate to renal surgery; Informed consent signed.
Exclusion: Contraindication for MRI.